CClinicalTrials.gg
CompletedNCT05715034Updated Apr 19, 2023

Single-Session Web-Based Training in Self-Compassion

An interventional study of Compassionate Care and Relaxing with Nature in Stress, Anxiety and Depression, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
365
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Two-arm, parallel group randomized clinical trial conducted via Mturk comparing a single-session web-based intervention called Compassionate Care versus a control intervention (nature videos with relaxing music) for adults with moderate-to-severe stress, depression and/or anxiety symptoms.

Read the detailed description

Procedures include completing: (1) pre-intervention baseline assessment; (2) one of two single-session web-based intervention (approximately 30 to 45 minutes each); (3) a brief post-intervention survey; and (4) a 2-week follow-up assessment.

02

Conditions studied

  • Stress
  • Anxiety
  • Depression

Keywords

  • Randomized controlled trial
  • Self-Compassion
03

In context

Depression

8,055 studies on the registry are indexed under Depression; 1,643 are open to participants now.

This study's enrollment of 365 is above the median of 84 across 6,718 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.

Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18 years of age or older
  • Fluent in English
  • At least moderate stress, anxiety and/or depressive symptoms, as indicated by a score of:

    14 or higher on the PSS-10, and/or 10 or higher on the GAD-7, and/or 10 or higher on the PHQ-9

Exclusion criteria

Exclusion Criteria:

  • Fail to meet above-listed inclusion criteria
  • Do not pass attention/data quality checks in initial screening or study assessments, including:
  • Obvious lack of English fluency in open response questions
  • Responding with random text in open response questions
  • Respond with either copy/pasted responses from text earlier in the intervention to any of free response questions
  • Participants with a completion time less than an average of 1.5 seconds per question for the baseline survey assessment OR who fail all three attention check questions in the baseline survey, indicating very careless, random, inattentive and/or hasty responding
  • Exit the study prior to condition randomization
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
365 participants (actual)

Study arms

  • Experimental
    Compassionate Care

    Single-session, self-guided web-based intervention (\~45 minutes) hosted on Qualtrics with animated videos, audio-guided exercises, graphics, text-based material, and interactive questions. This intervention is designed to teach participants about mindfulness and self-compassion.

    Behavioral: Compassionate Care

  • Active comparator
    Relaxing with Nature

    Single-session self-guided web-based intervention (\~30 to 45 minutes) hosted on Qualtrics with videos (real-life images), text-based material, and questions. Each video includes a sequence of pleasant nature photos (shown about 6 seconds each) with relaxing music in the background.

    Behavioral: Relaxing with Nature

Interventions

  • BehavioralCompassionate Care

    Single-session web-based program

  • BehavioralRelaxing with Nature

    Single-session web-based program

06

What researchers measure

Primary outcomes

  1. Change in Stress symptoms

    Perceived Stress Scale (PSS-10). Total scores range from 0 to 40 with higher scores indicating greater stress symptoms

    Time frame: Baseline to 2-week follow-up

  2. Change in Anxiety symptoms

    General Anxiety Disorder-7 (GAD-7). Total scores range from 0 to 21, with higher scores indicating greater anxiety symptoms.

    Time frame: Baseline to 2-week follow-up

  3. Change in Depressive symptoms

    Patient Health Questionnaire-9 (PHQ-9). Total scores range from 0 to 27, with higher scores indicating greater depressive symptoms.

    Time frame: Baseline to 2-week follow-up

  4. Change in Functional Impairment

    Work and Social Adjustment Scale (WSAS). Total scores range from 0 to 40, with higher scores indicating greater functional impairment.

    Time frame: Baseline to 2-week follow-up

Secondary outcomes

  1. Change in Self-Compassion

    Self-Compassion Scale (SCS). Total scores are the average of each of the subscales, and range from 0 to 5. Higher scores indicate greater self-compassion.

    Time frame: Baseline to 2-week follow-up

  2. Change in Mindfulness

    Cognitive and Affective Mindfulness Scale-Revised (CAMS-R). Total scores range from 0 to 40, with higher scores indicating greater mindfulness.

    Time frame: Baseline to 2-week follow-up

07

Study locations

1 site
  • Yale
    New Haven, Connecticut 06511, United States
08

References and documents

Individual participant data

Plan to share: Yes — In compliance with HIPAA and Yale Human Investigation Committee standards, any data sets that will be shared will not include any personally identifiable information. Requests for data sharing will be considered within the context of ongoing and planned research being performed within the research group at Yale in order to avoid duplication of effort and overlap in data analysis that might compromise communication of findings. Data to be shared will be de-identified and transmission electronically and securely, as we have done previously with investigators at other institutions.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05715034
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Feb 6, 2023
Start date
Feb 27, 2023
Primary completion
Apr 17, 2023
Completion
Apr 17, 2023
Last update
Apr 19, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion